Papers
Topics
Authors
Recent
Detailed Answer
Quick Answer
Concise responses based on abstracts only
Detailed Answer
Well-researched responses based on abstracts and relevant paper content.
Custom Instructions Pro
Preferences or requirements that you'd like Emergent Mind to consider when generating responses
Gemini 2.5 Flash
Gemini 2.5 Flash 91 tok/s
Gemini 2.5 Pro 54 tok/s Pro
GPT-5 Medium 16 tok/s Pro
GPT-5 High 20 tok/s Pro
GPT-4o 108 tok/s Pro
Kimi K2 212 tok/s Pro
GPT OSS 120B 471 tok/s Pro
Claude Sonnet 4 38 tok/s Pro
2000 character limit reached

Meta-analysis of median survival times with inverse-variance weighting (2503.03065v1)

Published 5 Mar 2025 in stat.ME

Abstract: We consider the problem of meta-analyzing outcome measures based on median survival times, such as the difference of median survival times between groups. Primary studies with time-to-event outcomes often report estimates of median survival times and corresponding confidence intervals based on the Kaplan-Meier estimator. However, applying conventional inverse-variance weighted methods to meta-analyze outcome measures based on median survival is often challenging because within-study standard error estimates are typically not available in this setting. In this article, we consider an inverse-variance weighted approach to meta-analyze median survival times that estimates the within-study standard errors from the reported confidence intervals. We conduct a series of simulation studies evaluating the performance of this approach at the study level (i.e., for estimating the standard error of median survival) and the meta-analytic level (i.e., for estimating the pooled median, difference of medians, and ratio of medians). We find that this approach often performs comparable to a benchmark approach that uses the true within-study standard errors for meta-analyzing median-based outcome measures. We then illustrate an application of this approach in a meta-analysis evaluating survival benefits of being assigned to experimental arms versus comparator arms in randomized trials for non-small cell lung cancer therapies.

List To Do Tasks Checklist Streamline Icon: https://streamlinehq.com

Collections

Sign up for free to add this paper to one or more collections.

Summary

We haven't generated a summary for this paper yet.

Dice Question Streamline Icon: https://streamlinehq.com

Follow-Up Questions

We haven't generated follow-up questions for this paper yet.